Market Tracker

06/30 5:16pm ET

OPKO Health Inc (NASDAQ:OPK)

9.34
Delayed Data
As of Jun 30
 +0.04 / +0.43%
Today’s Change
7.12
Today|||52-Week Range
17.51
-7.06%
Year-to-Date
Opko Is a Buying Opportunity After FDA's Approval of Kidney Drug
Jun 30 / TheStreet.com - Paid Partner Content
Is Opko Health a Buy Now That Rayaldee Is Approved?
Jun 21 / MotleyFool.com - Paid Partner Content
Opko Health Inc (OPK) CEO & Chairman, 10% Owner Phillip Frost Bought $169,200 of Sto...
Jun 28 / GuruFocus News - Paid Partner Content
Why Sprint, Energy Transfer Equity, and Opko Health Jumped Today
Jun 21 / MotleyFool.com - Paid Partner Content
Opko Health Inc (OPK) CEO & Chairman, 10% Owner Phillip Frost Bought $169,560 of Sto...
Jun 24 / GuruFocus News - Paid Partner Content
Here's Why Opko Health (OPK) Stock Is Gaining Today
Jun 21 / Zacks.com - Paid Partner Content
Opko Health (OPK) Catches Eye: Stock Adds 5.6% in Session
Jun 22 / Zacks.com - Paid Partner Content
Company News for June 21, 2016
Jun 21 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close9.30
Today’s open9.12
Day’s range9.07 - 9.46
Volume3,613,448
Average volume (3 months)3,916,995
Market cap$5.1B
Dividend yield--
Data as of 3:59pm ET, 06/30/2016

Growth & Valuation

Earnings growth (last year)+85.37%
Earnings growth (this year)-5.55%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+439.63%
P/E ratio63.8
Price/Sales9.97
Price/Book2.56

Competitors

 Today’s
change
Today’s
% change
UTHRUnited Therapeutics ...+2.38+2.30%
SGENSeattle Genetics Inc+0.05+0.12%
----
GRFSGrifols SA+0.78+4.91%
Data as of 4:00pm ET, 06/30/2016

Financials

Next reporting dateAugust 3, 2016
EPS forecast (this quarter)$0.01
Annual revenue (last year)$491.7M
Annual profit (last year)-$30.0M
Net profit margin-6.11%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Phillip Frost
Chief Financial Officer, Treasurer, CAO &
SVP
Adam E. Logal
Corporate headquarters
Miami, Florida

Forecasts